Drug Profile
bb 21217
Alternative Names: Anti-BCMA CAR T-cell- bluebird bio/Celgene; BB 212172; bb21217Latest Information Update: 21 Nov 2023
Price :
$50
*
At a glance
- Originator bluebird bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 11 Jan 2022 Discontinued - Phase-I for Multiple myeloma (Second-line therapy or greater) in USA (Parenteral) due to portfolio prioritization
- 11 Dec 2021 Updated safety and efficacy data from a phase I trial in Multiple myeloma presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)
- 05 Dec 2020 Updated safety, efficacy and pharmacodynamics data from a phase I trial in Multiple myeloma presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2020)